β-cardiac myosin mediates cardiac muscle contraction within the sarcomere by binding to the thin filament in an ATP-powered reaction. This process is highly regulated on a beat-to-beat basis by calcium interactions with the thin filament, but also contractile force is highly regulated by controlling the number of myosins available, resulting in a dynamic reserve. Our goal was to examine the size of this reserve and how it is modulated by cardiac myosin binding protein-C (cMyBP-C). We used single-molecule imaging to determine myosin activity with high spatial resolution by measuring fluorescently tagged ATP molecules binding to and releasing from myosins within the cardiac sarcomere. Three myosin ATPase states were detected: the fastest species was consistent with nonspecific ATP binding to myosin’s surface, and the slower two species were consistent with the previously identified DRX and SRX states. The former represents myosins in a state ready to interact with the thin filament, and the latter in a cardiac reserve state with slowed ATPase. We found the cardiac reserve was 46% across the whole sarcomere in porcine myofibrils. Subdividing into the P-, C-, and D-zones revealed the D-zone has the smallest population of reserve heads (44%). Treatment with PKA that phosphorylates cMyBP-C led to a 16% reduction of reserve in the C-zone (where cMyBP-C is found) and a 10% reduction in the P-zone, with an unexpected 15% increase in the D-zone. Interestingly, the changes in SRX myosin head distribution by PKA phosphorylation of cMyBP-C across each subsarcomeric zone mirror the changes we identified in human cardiac myofibrils isolated from a hypertrophic cardiomyopathy patient mutation (MYBPC3-c.772G>A) that exhibits cMyBP-C haploinsufficiency. These results provide novel insights into how the C-zone functions in both porcine and human β-cardiac myosin–containing thick filaments, revealing a possible compensatory change in the D-zone upon altered cMyBP-C phosphorylation and/or haploinsufficiency.
Background: Inhibiting contractility by targeting cardiac myosin is an effective treatment for patients with hypertrophic cardiomyopathy (HCM). Aficamten is a second in class myosin inhibitor with promising clinical data showing improvements in hemodynamics and symptoms in patients with HCM. While it is known that Aficamten inhibits force and cardiomyocyte contractility by stabilizing the weak pre-powerstroke conformation, effects on myosin structure and kinetics during loaded contraction are lacking. Methods: Permeabilized porcine cardiac tissue and myofibrils were used for single-molecule imaging of ATP turn over, X-ray diffraction, and mechanical measurements. Engineered heart tissues from human induced pluripotent stem cell cardiomyocytes were used to evaluate effects on force and contraction kinetics. Results: In contrast to Mavacamten, Aficamten does not structurally sequester myosin heads along the thick filament. Aficamten inhibits ATPase activity by shifting myosin heads from higher to slower ATPase state, with the emergence of a super slow biochemical nucleotide turnover state. This results in decreased force and calcium sensitivity without altering cross-bridge cycling. These contractile mechanical changes are comparable to Mavacamten. Our myofibril mechanical assay showed inhibition of force with accelerated relaxation. In EHTs, while Mavacamten and Aficamten inhibit cardiac twitch forces, Mavacamten reduces the activation kinetics while both result in faster relaxation. Conclusions: We used a combination of biochemical and biomechanical assays to show that Aficamten inhibits myosin ATPase without appreciably altering myosin structure. This is different from Mavacamten that strongly affects both. While both compounds inhibit contractility, differences in mechanisms of action and kinetics of force activation and relaxation could allow use in different patient populations.